HRP20191805T1 - Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća - Google Patents
Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća Download PDFInfo
- Publication number
- HRP20191805T1 HRP20191805T1 HRP20191805TT HRP20191805T HRP20191805T1 HR P20191805 T1 HRP20191805 T1 HR P20191805T1 HR P20191805T T HRP20191805T T HR P20191805TT HR P20191805 T HRP20191805 T HR P20191805T HR P20191805 T1 HRP20191805 T1 HR P20191805T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- patient
- use according
- amikacin
- period
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 208000019839 Pulmonary non-tuberculous mycobacterial infection Diseases 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 229960004821 amikacin Drugs 0.000 claims 6
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical group NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 claims 1
- 208000033126 Colobomatous microphthalmia Diseases 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims 1
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 claims 1
- 238000012387 aerosolization Methods 0.000 claims 1
- 229960001656 amikacin sulfate Drugs 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000034367 isolated with coloboma microphthalmia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000002691 unilamellar liposome Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Farmaceutski pripravak koji sadrži od 450 mg do 650 mg amikacina, ili njegove farmaceutski prihvatljive soli, ugrađenog u mnoštvu liposoma, gdje se lipidna komponenta mnoštva liposoma sastoji od dipalmitoilfosfatidilholina (DPPC) i kolesterola, namijenjena liječenju ili osiguravanju profilakse protiv infekcije pluća izazvane Mycobacterium avium kompleksom (MAC) kod pacijenta kome je potrebno liječenje ili profilaksa,
pri čemu se pripravak primjenjuje jednom dnevno u jednom doziranju, tokom perioda primijene od najmanje tri mjeseca, na pluća pacijenta aerosolizacijom farmaceutskog pripravka putem raspršivača da bi se osigurao aerosolizirani farmaceutski pripravak koji sadrži mješavinu slobodnog amikacina, ili njegove farmaceutski prihvatljive soli i liposomalno kompleksnog amikacina, ili njegove farmaceutski prihvatljive soli,
pri čemu tokom perioda primijene ili nakon perioda primijene, kod pacijenta dolazi do konverzije kulture MAC u negativnu.
2. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1, naznačen time, što tokom perioda primijene ili nakon perioda primijene, pacijent ostvaruje povećani broj prijeđenih metara u 6-minutnom testu hodanja (6MWT), u usporedbi sa brojem metara koje je pacijent prešao prije podvrgavanja postupku liječenja.
3. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 1 ili 2, naznačen time, što kod pacijenta dolazi do poboljšanja volumena prisilnog izdisanja u jednoj sekundi (FEV1) tokom najmanje 15 dana nakon završetka perioda primijene, u usporedbi sa FEV1 pacijenta prije liječenja.
4. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, što je amikacin ili njegova farmaceutski prihvatljiva sol amikacin sulfat.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 4, naznačen time, što liposom sadrži jednolamelarne vezikule, višelamelarne vezikule, ili njihovu mješavinu.
6. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time, što je volumen farmaceutskog pripravka koji je primijenjen kod pacijenta od oko 8 mL do oko 10 mL.
7. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time, što se tokom jednog doziranja, aerosolizirani farmaceutski pripravak primjenjuje za manje od oko 15 minuta, manje od oko 14 minuta, manje od oko 13 minuta, manje od oko 12 minuta, ili manje od oko 11 minuta.
8. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time, što pacijent kome je potrebno liječenje ili profilaksa prethodno nije odgovarao na terapiju protiv MAC.
9. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačen time, što je povećani broj uspoređenih metara u testu 6MWT najmanje oko 5 metara.
10. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-9, naznačen time, što poboljšanje FEV1 pacijenta iznosi najmanje 5% u odnosu na FEV1 pacijenta prije liječenja.
11. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-10, naznačen time, što farmaceutski pripravak sadrži od oko 550 mg do oko 625 mg amikacina, ili njegove farmaceutski prihvatljive soli.
12. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 11, naznačen time, što farmaceutski pripravak sadrži od oko 550 mg do oko 600 mg amikacina, ili njegove farmaceutski prihvatljive soli.
13. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, što kod pacijenta dolazi do poboljšanja zasićenosti krvi kisikom tokom najmanje 15 dana nakon završetka perioda primijene, u usporedbi sa zasićenošću krvi kisikom kod pacijenta prije perioda primijene.
14. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-13, naznačen time, što je period primijene najmanje oko 6 mjeseci.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461993439P | 2014-05-15 | 2014-05-15 | |
US201462042126P | 2014-08-26 | 2014-08-26 | |
US201462048068P | 2014-09-09 | 2014-09-09 | |
US201462056296P | 2014-09-26 | 2014-09-26 | |
PCT/US2015/031079 WO2015175939A1 (en) | 2014-05-15 | 2015-05-15 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
EP15791964.8A EP3142643B1 (en) | 2014-05-15 | 2015-05-15 | Methods for treating pulmonary non-tuberculous mycobacterial infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191805T1 true HRP20191805T1 (hr) | 2019-12-27 |
Family
ID=54480776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191805TT HRP20191805T1 (hr) | 2014-05-15 | 2019-10-03 | Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća |
Country Status (22)
Country | Link |
---|---|
US (13) | US10238675B2 (hr) |
EP (4) | EP3766501B1 (hr) |
JP (4) | JP6646653B2 (hr) |
KR (4) | KR102447412B1 (hr) |
CN (1) | CN106535877A (hr) |
AU (2) | AU2015258947B2 (hr) |
BR (1) | BR112016026699B1 (hr) |
CA (1) | CA2949078C (hr) |
CY (2) | CY1122129T1 (hr) |
DK (2) | DK3142643T3 (hr) |
ES (3) | ES2755941T3 (hr) |
HR (1) | HRP20191805T1 (hr) |
HU (1) | HUE051440T2 (hr) |
LT (2) | LT3466432T (hr) |
ME (1) | ME03536B (hr) |
MX (2) | MX2016014921A (hr) |
NZ (1) | NZ726256A (hr) |
PL (2) | PL3142643T3 (hr) |
PT (2) | PT3142643T (hr) |
RS (1) | RS60827B1 (hr) |
SI (2) | SI3142643T1 (hr) |
WO (1) | WO2015175939A1 (hr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1962805T3 (pl) | 2005-12-08 | 2017-01-31 | Insmed Incorporated | Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
CA2891487A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
NO2699580T3 (hr) | 2014-01-24 | 2018-02-24 | ||
PL3142643T3 (pl) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Sposoby leczenia zakażeń płuc prątkami niegruźliczymi |
US20180028541A1 (en) * | 2016-07-29 | 2018-02-01 | Astrazeneca Ab | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis |
US20210007985A1 (en) * | 2017-04-05 | 2021-01-14 | Aradigm Corporation | Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm |
BR112020007395A2 (pt) * | 2017-10-16 | 2020-09-29 | Drugrecure Aps | uso do fator estimulador de colônias de granulócitos e macrófagos, e, método de tratamento de uma infecção pulmonar por micobactérias não tuberculosas refratária |
CN108310393A (zh) * | 2018-02-12 | 2018-07-24 | 丹诺医药(苏州)有限公司 | 一种利福霉素-喹嗪酮偶联分子的应用 |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
US10736847B2 (en) | 2018-07-03 | 2020-08-11 | Becton, Dickinson And Company | Inverting device for liposome preparation by centrifugation |
EP3906251A4 (en) * | 2019-01-05 | 2022-10-05 | Foundation For Neglected Disease Research | THIAZOLYL PEPTIDES FOR THE TREATMENT OF NON-TUBERCULAR MYCOBACTERIAL INFECTIONS |
KR102275997B1 (ko) * | 2019-11-07 | 2021-07-13 | 연세대학교 산학협력단 | 숙주지향치료를 위한 조성물 |
US11808135B2 (en) | 2020-01-16 | 2023-11-07 | Halliburton Energy Services, Inc. | Systems and methods to perform a downhole inspection in real-time |
WO2022039506A1 (ko) * | 2020-08-19 | 2022-02-24 | 주식회사 미토이뮨테라퓨틱스 | Mabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제 |
CA3190401A1 (en) * | 2020-08-31 | 2022-03-03 | Kevin MANGE | Methods for treating newly diagnosed mycobacterium avium complex lung infections |
EP4313066A1 (en) * | 2021-03-24 | 2024-02-07 | Insmed Incorporated | Combination therapy for treating non-tuberculous mycobacterial lung disease |
US20240139148A1 (en) * | 2021-06-11 | 2024-05-02 | Colorado State University Research Foundation | Compositions and methods for treating non-tuberculous mycobacterial infections |
KR102596057B1 (ko) * | 2021-11-05 | 2023-11-01 | 연세대학교 산학협력단 | 마이코박테리움 아비움 복합체 감염질환 진단용 지질대사체 마커 |
KR102615869B1 (ko) * | 2021-11-05 | 2023-12-21 | 연세대학교 산학협력단 | 마이코박테리움 아비움 복합체 폐질환 환자의 정보에 따른 치료 반응 예측용 지질대사체 마커 |
KR102613631B1 (ko) * | 2021-11-05 | 2023-12-15 | 연세대학교 산학협력단 | 마이코박테리움 아비움 복합체 감염증의 중증도 예측용 대사체 마커 |
WO2023080663A1 (ko) * | 2021-11-05 | 2023-05-11 | 연세대학교 산학협력단 | 마이코박테리움 아비움 복합체 감염질환 진단 또는 중증도 예측용 대사체 마커 |
WO2023107923A1 (en) * | 2021-12-07 | 2023-06-15 | An2 Therapeutics, Inc. | Combinations |
Family Cites Families (358)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3006698A (en) | 1959-11-25 | 1961-10-31 | Gen Motors Corp | Bearing assembly |
US3061303A (en) | 1961-02-21 | 1962-10-30 | Didde Glaser Inc | Self-centering parallel guide assembly |
US3091572A (en) | 1962-07-16 | 1963-05-28 | Schering Corp | Gentamycin and method of production |
US3136704A (en) | 1962-12-05 | 1964-06-09 | Schering Corp | Manufacture of gentamycin |
US3852557A (en) | 1973-07-12 | 1974-12-03 | Cutler Hammer Inc | Electric switch with pivoting and wiping movable contractor |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
GB2046092B (en) | 1979-03-05 | 1983-11-02 | Toyama Chemical Co Ltd | Pharmaceutical composition containing a lysophospholid and a phospholipid |
HU184141B (en) | 1979-12-27 | 1984-07-30 | Human Oltoanyagtermelo | Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof |
US4451447A (en) | 1980-03-31 | 1984-05-29 | Bristol-Myers Company | Pharmaceutical formulations |
EP0069307B1 (de) | 1981-07-02 | 1986-03-05 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung von Liposomenlösungen |
US4547490A (en) | 1981-12-31 | 1985-10-15 | Neomed, Inc. | Synthetic whole blood and a method of making the same |
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4684625A (en) | 1982-07-08 | 1987-08-04 | Syntex (U.S.A.) Inc. | Method for enhancing the anti-infective activity of muramyldipeptide derivatives |
US4981692A (en) | 1983-03-24 | 1991-01-01 | The Liposome Company, Inc. | Therapeutic treatment by intramammary infusion |
US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US5169637A (en) | 1983-03-24 | 1992-12-08 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4515736A (en) | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
CA1237670A (en) | 1983-05-26 | 1988-06-07 | Andrew S. Janoff | Drug preparations of reduced toxicity |
US5059591B1 (en) | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
US4606939A (en) | 1983-06-22 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation |
CA1237671A (en) | 1983-08-01 | 1988-06-07 | Michael W. Fountain | Enhancement of pharmaceutical activity |
GB8322178D0 (en) | 1983-08-17 | 1983-09-21 | Sterwin Ag | Preparing aerosol compositions |
WO1985000968A1 (en) | 1983-09-06 | 1985-03-14 | Health Research, Inc. | Liposome delivery method for decreasing the toxicity of an antitumor drug |
US4721612A (en) | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5008050A (en) | 1984-06-20 | 1991-04-16 | The Liposome Company, Inc. | Extrusion technique for producing unilamellar vesicles |
SE8403905D0 (sv) | 1984-07-30 | 1984-07-30 | Draco Ab | Liposomes and steroid esters |
US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
AU587472B2 (en) | 1985-05-22 | 1989-08-17 | Liposome Technology, Inc. | Liposome inhalation method and system |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
US5409704A (en) | 1985-06-26 | 1995-04-25 | The Liposome Company, Inc. | Liposomes comprising aminoglycoside phosphates and methods of production and use |
JP2579625B2 (ja) | 1985-07-05 | 1997-02-05 | ザ リポソ−ム カンパニ−,インコ−ポレイテツド | 改良された取り込み効率を有するマルチラメラリポソ−ム |
JPH0665648B2 (ja) | 1985-09-25 | 1994-08-24 | 塩野義製薬株式会社 | 白金系抗癌物質の安定な凍結真空乾燥製剤 |
US5041278A (en) | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
US4861580A (en) | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
US5041581A (en) | 1985-10-18 | 1991-08-20 | The University Of Texas System Board Of Regents | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
US5023087A (en) | 1986-02-10 | 1991-06-11 | Liposome Technology, Inc. | Efficient method for preparation of prolonged release liposome-based drug delivery system |
US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
US4833134A (en) | 1986-08-19 | 1989-05-23 | Takeda Chemical Industries, Ltd. | Cephem compounds |
US5049388A (en) | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
US4933121A (en) | 1986-12-10 | 1990-06-12 | Ciba Corning Diagnostics Corp. | Process for forming liposomes |
US5320906A (en) | 1986-12-15 | 1994-06-14 | Vestar, Inc. | Delivery vehicles with amphiphile-associated active ingredient |
DE3751871D1 (de) | 1986-12-23 | 1996-09-19 | Liposome Co Inc | Guanidinaminoglycosid enthaltende Liposome |
US5723147A (en) | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
US5616334A (en) | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
WO1989000846A1 (en) | 1987-07-29 | 1989-02-09 | The Liposome Company, Inc. | Method for size separation of particles |
US4857311A (en) | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
US4895452A (en) | 1988-03-03 | 1990-01-23 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
MX9203504A (es) | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
US5269979A (en) | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
BE1001869A3 (fr) | 1988-10-12 | 1990-04-03 | Franz Legros | Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine. |
US4952405A (en) | 1988-10-20 | 1990-08-28 | Liposome Technology, Inc. | Method of treating M. avium infection |
US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
US5006343A (en) | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
US5843473A (en) | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
WO1991009616A1 (en) | 1989-12-22 | 1991-07-11 | Yale University | Quinolone antibiotics encapsulated in lipid vesicles |
US5820848A (en) | 1990-01-12 | 1998-10-13 | The Liposome Company, Inc. | Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991016882A1 (en) | 1990-05-08 | 1991-11-14 | Liposome Technology, Inc. | Direct spray-dried drug/lipid powder composition |
US6623671B2 (en) | 1990-10-05 | 2003-09-23 | Royden M. Coe | Liposome extrusion process |
US5614216A (en) | 1990-10-17 | 1997-03-25 | The Liposome Company, Inc. | Synthetic lung surfactant |
IT1245761B (it) | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. |
EP0525132B1 (en) | 1991-02-14 | 1996-01-03 | Baxter International Inc. | Binding of recognizing substances to liposomes |
US5228346A (en) | 1991-04-08 | 1993-07-20 | Marathon Oil Company | Method of determining gas flow volume |
US6629646B1 (en) | 1991-04-24 | 2003-10-07 | Aerogen, Inc. | Droplet ejector with oscillating tapered aperture |
EP0540775B1 (de) | 1991-11-07 | 1997-07-23 | PAUL RITZAU PARI-WERK GmbH | Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie |
US5770563A (en) | 1991-12-06 | 1998-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
AU3467193A (en) | 1991-12-17 | 1993-07-19 | Regents Of The University Of California, The | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (CFTR) |
US6890555B1 (en) | 1992-02-05 | 2005-05-10 | Qlt, Inc. | Liposome compositions of porphyrin photosensitizers |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5871710A (en) | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
AU3244393A (en) | 1992-12-02 | 1994-06-22 | Vestar, Inc. | Antibiotic formulation and process |
US5958449A (en) | 1992-12-02 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for bacterial infections |
US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
ZA938381B (en) | 1993-03-22 | 1994-06-13 | Inland Steel Co | Apparatus and method for magnetically confining molten metal using concentrating fins |
WO1994022430A1 (en) | 1993-04-02 | 1994-10-13 | The Liposome Company, Inc. | Method of producing liposomes |
CA2120197A1 (en) | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
US5759571A (en) | 1993-05-11 | 1998-06-02 | Nexstar Pharmaceuticals, Inc. | Antibiotic formulation and use for drug resistant infections |
US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
JPH06345663A (ja) | 1993-06-08 | 1994-12-20 | Sumitomo Pharmaceut Co Ltd | バンコマイシン含有リポソーム製剤 |
ES2154680T3 (es) | 1993-07-08 | 2001-04-16 | Liposome Co Inc | Metodo para controlar el tamaño de los liposomas. |
CA2101241C (en) | 1993-07-23 | 1998-12-22 | Jonathan P. Wong | Liposome-encapsulated ciprofloxacin |
CA2153251C (en) | 1993-11-05 | 1998-09-01 | David Samuel Collins | Liposome preparation and material encapsulation method |
US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
CA2178902A1 (en) | 1993-12-14 | 1995-06-22 | Drew Pardoll | Controlled release of pharmaceutically active substances for immunotherapy |
ATE168289T1 (de) | 1993-12-17 | 1998-08-15 | Pari Gmbh | Zerstäuberdüse |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US5610198A (en) | 1994-03-18 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases |
DE59409856D1 (de) | 1994-05-19 | 2001-10-11 | Pari Gmbh | Vorrichtung zur Trocknung und Pufferung von Aerosolen |
US5550109A (en) | 1994-05-24 | 1996-08-27 | Magainin Pharmaceuticals Inc. | Inducible defensin peptide from mammalian epithelia |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5993850A (en) | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
US6000394A (en) | 1994-10-26 | 1999-12-14 | Paul Rizau Pari-Werk Gmbh | Generation of an aerosol of an exact dose |
SA95160463B1 (ar) | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
US5662929A (en) | 1994-12-23 | 1997-09-02 | Universite De Montreal | Therapeutic liposomal formulation |
US5883074A (en) | 1995-02-08 | 1999-03-16 | Microcide Pharmaceuticals, Inc. | Potentiators of antibacterial agents |
US5972379A (en) | 1995-02-14 | 1999-10-26 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering a quinolone |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
EP0825852B1 (en) | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
US5855610A (en) | 1995-05-19 | 1999-01-05 | Children's Medical Center Corporation | Engineering of strong, pliable tissues |
CA2220950A1 (en) | 1995-05-26 | 1996-11-28 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
NZ309624A (en) | 1995-06-06 | 1999-04-29 | Bayer Ag | Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions |
DE19520622C2 (de) | 1995-06-06 | 2003-05-15 | Pari Gmbh | Vorrichtung zum Vernebeln von Fluiden |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
JPH11507697A (ja) | 1995-06-09 | 1999-07-06 | エヌ. ドロハン,ウィリアム | キチンヒドロゲル、それらの製造方法及び利用 |
US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
WO1997014740A1 (en) | 1995-10-19 | 1997-04-24 | Receptagen Corporation | Discrete-length polyethylene glycols |
DE19602628C2 (de) | 1996-01-25 | 2000-06-29 | Pari Gmbh | Vernebler |
GB9602969D0 (en) | 1996-02-13 | 1996-04-10 | The Technology Partnership Plc | Liquid supply apparatus |
US5840702A (en) | 1996-03-22 | 1998-11-24 | Uab Research Foundation | Cystic fibrosis treatment |
EP0914094A4 (en) | 1996-03-28 | 2000-03-01 | Univ Illinois | MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS |
US5875776A (en) | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
CA2174803C (en) | 1996-04-23 | 2000-07-11 | Jonathan P. Wong | Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug |
DE19616573C2 (de) | 1996-04-25 | 1999-03-04 | Pari Gmbh | Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase |
WO1997040835A1 (en) | 1996-04-26 | 1997-11-06 | Magainin Pharmaceuticals Inc. | Treatment of carcinomas using squalamine in combination with other anti-cancer agents |
GB9609779D0 (en) | 1996-05-10 | 1996-07-17 | Univ Bruxelles | Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
US6503881B2 (en) | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
DK0929293T3 (da) | 1996-08-23 | 2004-02-02 | Sequus Pharm Inc | Liposomer indeholdende en cisplatinforbindelse |
TW520297B (en) | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
US6451784B1 (en) | 1996-12-30 | 2002-09-17 | Battellepharma, Inc. | Formulation and method for treating neoplasms by inhalation |
BR9713661A (pt) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulação e método para o tratamento de neoplasmas por inalação |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
DE19713636A1 (de) | 1997-04-02 | 1998-10-08 | Pari Gmbh | Atemzugsimulator |
US20020039594A1 (en) | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US5957339A (en) | 1997-06-23 | 1999-09-28 | Keystone Manufacturing Co., Inc. | Water filtration system |
JP4142149B2 (ja) | 1997-07-10 | 2008-08-27 | 明治製菓株式会社 | バンコマイシンの凍結乾燥製剤 |
DE19734022C2 (de) | 1997-08-06 | 2000-06-21 | Pari Gmbh | Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses |
US6106858A (en) | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
CA2215716C (en) | 1997-09-17 | 1999-12-07 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Aerosol delivery of liposome-encapsulated fluoroquinolone |
US6090407A (en) | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
PT1024814E (pt) | 1997-10-22 | 2007-11-29 | Mayo Foundation | Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo |
EP1030652B1 (en) | 1997-11-14 | 2012-04-25 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
US6051251A (en) | 1997-11-20 | 2000-04-18 | Alza Corporation | Liposome loading method using a boronic acid compound |
AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
GB9827370D0 (en) | 1998-01-16 | 1999-02-03 | Pari Gmbh | Mouthpiece for inhalation therapy units |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
ES2273493T3 (es) | 1998-05-27 | 2007-05-01 | Euro-Celtique S.A. | Uso de preparados para la aplicacion de agentes antisepticos y/o agentes que favorecen la curacion de heridas al tracto respiratorio inferior. |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
DE19827228C2 (de) | 1998-06-18 | 2000-07-13 | Pari Gmbh | Flüssigkeitszerstäubervorrichtung |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
AU754559B2 (en) | 1998-08-12 | 2002-11-21 | New York University | Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient |
DE19846382C1 (de) | 1998-10-08 | 2000-07-06 | Pari Gmbh | Zählwerk und seine Verwendung in Inhalatoren, Verneblern oder ähnlichen Dosieraerosolvorrichtungen |
CZ20011581A3 (cs) | 1998-11-12 | 2001-12-12 | Frank G. Pilkiewicz | Systém pro podávání bioaktivní sloučeniny inhalací |
JP2002529240A (ja) | 1998-11-13 | 2002-09-10 | オプタイム セラピュウティクス, インコーポレイテッド | リポソーム生成のための方法および装置 |
US6855296B1 (en) | 1998-11-13 | 2005-02-15 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
EP1161247A4 (en) | 1998-12-17 | 2002-05-15 | Chiron Corp | Treatment method for severe chronic bronchitis (bronchiectasis) using an antibiotic aerosol |
US6211162B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc. Inc. | Pulmonary delivery of protonated/acidified nucleic acids |
KR20010101837A (ko) | 1999-02-08 | 2001-11-14 | 스톤 스티븐 에프. | 리포좀 크기 조절 방법 |
EP1173193A4 (en) | 1999-04-02 | 2003-01-29 | Univ Princeton | DES-LEUCYL GLYCOPEPTIDE ANTIBIOTICS AND METHOD OF PREPARATION |
US6613352B2 (en) | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
WO2000074634A2 (en) | 1999-06-03 | 2000-12-14 | Au Jessie L S | Methods and compositions for modulating cell proliferation and cell death |
EP1190705A4 (en) | 1999-06-24 | 2009-03-18 | Kyowa Hakko Kogyo Kk | METHOD OF REGULATING THE TREATMENT OF LABELED SUBSTANCE IN LIPOSOMES |
IL147089A0 (en) | 1999-07-15 | 2002-08-14 | Inex Pharmaceuticals Corp | Methods of preparing lipid-encapsulated therapeutic agents |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6174878B1 (en) | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
US6235177B1 (en) | 1999-09-09 | 2001-05-22 | Aerogen, Inc. | Method for the construction of an aperture plate for dispensing liquid droplets |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
DE19953317C1 (de) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
JP4198850B2 (ja) | 1999-11-29 | 2008-12-17 | オムロンヘルスケア株式会社 | 液体噴霧装置 |
JP2003515568A (ja) | 1999-12-04 | 2003-05-07 | リサーチ ディベロップメント ファンデーション | 吸入療法における二酸化炭素増強 |
DE10004465A1 (de) | 2000-02-02 | 2001-08-16 | Pari Gmbh | Inhalationsvernebler |
WO2001056548A2 (en) | 2000-02-04 | 2001-08-09 | Lipoxen Technologies Limited | Liposomes composition produced by a dehydration-rehydration process |
US6761877B2 (en) | 2000-02-18 | 2004-07-13 | Biocrystal, Ltd. | Functionalized encapsulated fluorescent nanocrystals |
US7758888B2 (en) | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
US7100600B2 (en) | 2001-03-20 | 2006-09-05 | Aerogen, Inc. | Fluid filled ampoules and methods for their use in aerosolizers |
MXPA02010884A (es) | 2000-05-05 | 2003-03-27 | Aerogen Ireland Ltd | Aparato y metodo para el suministro de medicamentos al sistema respiratorio. |
US7971588B2 (en) | 2000-05-05 | 2011-07-05 | Novartis Ag | Methods and systems for operating an aerosol generator |
US6948491B2 (en) | 2001-03-20 | 2005-09-27 | Aerogen, Inc. | Convertible fluid feed system with comformable reservoir and methods |
US7600511B2 (en) | 2001-11-01 | 2009-10-13 | Novartis Pharma Ag | Apparatus and methods for delivery of medicament to a respiratory system |
US8336545B2 (en) | 2000-05-05 | 2012-12-25 | Novartis Pharma Ag | Methods and systems for operating an aerosol generator |
EP1292314A2 (en) | 2000-05-23 | 2003-03-19 | The Trustees of Columbia University in the City of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans |
US6338859B1 (en) | 2000-06-29 | 2002-01-15 | Labopharm Inc. | Polymeric micelle compositions |
US6521736B2 (en) | 2000-09-15 | 2003-02-18 | University Of Massachusetts | Amphiphilic polymeric materials |
BR0114713A (pt) | 2000-10-16 | 2004-01-13 | Neopharm Inc | Formulação lipossÈmica de mitoxantrona |
CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
US6497901B1 (en) | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
EP1203614A1 (de) | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
JP2004522717A (ja) | 2000-12-01 | 2004-07-29 | バイオミラ,インコーポレイテッド | Pegへの注入による大型リポソームの作製 |
DE10102846B4 (de) | 2001-01-23 | 2012-04-12 | Pari Pharma Gmbh | Aerosolgenerator |
JP2004537501A (ja) | 2001-02-01 | 2004-12-16 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム | 肺への遺伝子送達のための安定化ポリマーエアロゾル |
DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
US6546927B2 (en) | 2001-03-13 | 2003-04-15 | Aerogen, Inc. | Methods and apparatus for controlling piezoelectric vibration |
JP2002318193A (ja) | 2001-04-24 | 2002-10-31 | Canon Inc | ネブライザ及び高周波誘導結合プラズマ発光分析装置 |
US6732944B2 (en) | 2001-05-02 | 2004-05-11 | Aerogen, Inc. | Base isolated nebulizing device and methods |
US6554201B2 (en) | 2001-05-02 | 2003-04-29 | Aerogen, Inc. | Insert molded aerosol generator and methods |
DE60210402T2 (de) | 2001-05-18 | 2006-12-07 | Chiron Corp., Emeryville | System zur Abgabe einer Tobramycin-Formulierung |
US20030060451A1 (en) | 2001-05-29 | 2003-03-27 | Rajneesh Taneja | Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin |
DE10126808C1 (de) | 2001-06-01 | 2002-08-14 | Pari Gmbh | Inhalationsmaske |
DE10126807C2 (de) | 2001-06-01 | 2003-12-04 | Pari Gmbh | Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses |
EP1269993A1 (en) | 2001-06-21 | 2003-01-02 | Applied NanoSystems B.V. | Delivery of small hydrophilic molecules packaged into lipid vesicles |
US6991809B2 (en) | 2001-06-23 | 2006-01-31 | Lyotropic Therapeutics, Inc. | Particles with improved solubilization capacity |
WO2003015698A2 (en) | 2001-08-13 | 2003-02-27 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
EP1424889A4 (en) | 2001-08-20 | 2008-04-02 | Transave Inc | PROCESS FOR TREATING LUNG CANCERS |
US6623723B2 (en) | 2001-08-21 | 2003-09-23 | Cellular Sciences Inc. | Method for treating bronchial constriction and bronchospasm |
OA12845A (en) * | 2001-08-21 | 2006-09-15 | Pfizer Prod Inc | Single dose azithromycin for treating respiratory infections. |
ATE269735T1 (de) | 2001-10-18 | 2004-07-15 | Pari Gmbh | Inhalationstherapievorrichtung |
DE50106644D1 (de) | 2001-10-18 | 2005-08-04 | Pari Gmbh | Inhalationstherapievorrichtung |
CN1608133A (zh) | 2001-10-26 | 2005-04-20 | 里伯药品公司 | 双链核糖核酸用于治疗正(+)链rna病毒感染的用途 |
US20030096774A1 (en) | 2001-11-21 | 2003-05-22 | Igor Gonda | Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
AU2003235678A1 (en) | 2002-01-15 | 2003-07-30 | Aerogen, Inc. | Systems and methods for clearing aerosols from the effective anatomic dead space |
WO2003059424A1 (en) | 2002-01-15 | 2003-07-24 | Aerogen, Inc. | Methods and systems for operating an aerosol generator |
CA2477979A1 (en) | 2002-03-05 | 2003-09-18 | Transave, Inc. | An inhalation system for treatment of intracellular infections |
US20030205226A1 (en) | 2002-05-02 | 2003-11-06 | Pre Holding, Inc. | Aerosol medication inhalation system |
ES2572770T3 (es) | 2002-05-20 | 2016-06-02 | Novartis Ag | Aparato para proporcionar pulverización para tratamiento médico y métodos |
DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
EP1386672B1 (en) | 2002-08-02 | 2010-04-07 | PARI Pharma GmbH | Fluid droplet production apparatus |
CN1681478A (zh) | 2002-08-02 | 2005-10-12 | 川塞夫有限公司 | 铂聚集体及其制备方法 |
WO2004017944A1 (en) | 2002-08-23 | 2004-03-04 | Neopharm, Inc. | Liposomal gemcitabine compositions for better drug delivery |
DE10239321B3 (de) | 2002-08-27 | 2004-04-08 | Pari GmbH Spezialisten für effektive Inhalation | Aerosoltherapievorrichtung |
KR100489701B1 (ko) | 2002-10-09 | 2005-05-16 | 주식회사 태평양 | 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법 |
MXPA05004580A (es) | 2002-10-29 | 2005-07-26 | Transave Inc | Liberacion sostenida de anti - infecciosos. |
US7879351B2 (en) | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
DE10250625A1 (de) | 2002-10-30 | 2004-05-19 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung |
AU2003298738A1 (en) | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
DE10257381B4 (de) | 2002-12-09 | 2006-09-14 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung |
US7968115B2 (en) | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
PT1615646E (pt) | 2003-04-08 | 2015-02-12 | Progenics Pharm Inc | Formulações farmacêuticas com metilnaltrexona |
US6900184B2 (en) | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
DE10320143A1 (de) | 2003-05-06 | 2004-12-16 | Pari GmbH Spezialisten für effektive Inhalation | Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen |
DE10322505B4 (de) | 2003-05-19 | 2009-11-05 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapiemaske und -vorrichtung für Tiere |
US8058493B2 (en) | 2003-05-21 | 2011-11-15 | Baker Hughes Incorporated | Removing amines from hydrocarbon streams |
EP1628637A2 (en) | 2003-05-30 | 2006-03-01 | Alza Corporation | Method of pulmonary administration of an agent |
US8616195B2 (en) | 2003-07-18 | 2013-12-31 | Novartis Ag | Nebuliser for the production of aerosolized medication |
JPWO2005019472A1 (ja) | 2003-08-20 | 2006-10-19 | 株式会社ロコモジェン | シノビオリン活性調節作用の検出方法 |
GB2388581A (en) | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
DE10345950A1 (de) | 2003-10-02 | 2005-05-19 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung mit Ventil |
DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
DE10348237A1 (de) | 2003-10-16 | 2005-05-19 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung mit einem Düsenvernebler |
US20050214224A1 (en) | 2003-11-04 | 2005-09-29 | Nektar Therapeutics | Lipid formulations for spontaneous drug encapsulation |
JP5044829B2 (ja) | 2003-12-31 | 2012-10-10 | ザ ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | トロンビンペプチド誘導体のための医薬組成物 |
US7452524B2 (en) | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Method for improvement of tolerance for therapeutically effective agents delivered by inhalation |
US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
DE102004016985B4 (de) | 2004-04-07 | 2010-07-22 | Pari Pharma Gmbh | Aerosolerzeugungsvorrichtung und Inhalationsvorrichtung |
JP4452799B2 (ja) | 2004-07-14 | 2010-04-21 | 独立行政法人産業技術総合研究所 | コアセルベートを活用したリポソームの製造方法 |
AU2005302255A1 (en) | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
AU2005306533B2 (en) | 2004-11-17 | 2012-05-31 | Arbutus Biopharma Corporation | siRNA silencing of apolipoprotein B |
US8337815B2 (en) | 2004-12-23 | 2012-12-25 | Discovery Laboratories, Inc. | Pulmonary surfactant formulations |
DE102005006375B4 (de) | 2005-02-11 | 2007-10-11 | Pari GmbH Spezialisten für effektive Inhalation | Aerosolerzeugungsvorrichtung für Inhalationstherapiegeräte |
DE102005006374B3 (de) | 2005-02-11 | 2006-07-20 | Pari GmbH Spezialisten für effektive Inhalation | Aerosolerzeugungsvorrichtung und Inhalationstherapiegerät mit einer derartigen Vorrichtung |
DE102005006372B4 (de) | 2005-02-11 | 2007-11-29 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung und Verfahren zu deren Betrieb |
US20060198940A1 (en) | 2005-03-04 | 2006-09-07 | Mcmorrow David | Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance |
JP2006263054A (ja) | 2005-03-23 | 2006-10-05 | Konica Minolta Sensing Inc | 呼吸器系疾患関連解析データの取得方法、オキシメータシステム及びその動作プログラム、オキシメータ並びに酸素補給システム |
EP1712220A1 (en) | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
CA2607747C (en) | 2005-05-25 | 2015-12-01 | Aerogen, Inc. | Vibration systems and methods |
DE102005024779B4 (de) | 2005-05-31 | 2008-02-21 | Pari GmbH Spezialisten für effektive Inhalation | Atemzuggesteuerte Inhalationstherapievorrichtung |
DE102005029498B4 (de) | 2005-06-24 | 2007-08-30 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung |
USD656604S1 (en) | 2005-06-28 | 2012-03-27 | Pari Gmbh | Part for inhalation therapy nebuliser |
DE102005034403B3 (de) | 2005-07-22 | 2007-02-22 | Airbus Deutschland Gmbh | Führungsmittel für eine Vorrichtung zur Herstellung von Faservorformlingen im TFP-Verfahren für Verbundbauteile |
CA2616877C (en) | 2005-07-27 | 2014-01-28 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
DE602006014695D1 (de) | 2005-08-31 | 2010-07-15 | Toray Industries | Mehrlagige polymilchsäureharzfolie und daraus geformter körper |
EP1926424B1 (en) | 2005-09-07 | 2009-08-19 | Philips Intellectual Property & Standards GmbH | System and method for inductively measuring the bio-impedance of a conductive tissue |
US20070065367A1 (en) | 2005-09-20 | 2007-03-22 | Rany Condos | Method of treating pulmonary disease with interferons |
KR100705981B1 (ko) | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물 |
US20070105757A1 (en) | 2005-10-31 | 2007-05-10 | May Thomas B | Vancomycin formulations having reduced amount of histamine |
DE102006051512A1 (de) | 2005-12-06 | 2007-06-14 | Pari GmbH Spezialisten für effektive Inhalation | Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin |
PL1962805T3 (pl) | 2005-12-08 | 2017-01-31 | Insmed Incorporated | Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych |
DE102006001113B3 (de) | 2006-01-09 | 2007-06-28 | Pari GmbH Spezialisten für effektive Inhalation | Aerosoltherapievorrichtung |
US8263645B2 (en) | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
DE102006006183A1 (de) | 2006-02-10 | 2007-08-16 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung für die Anwendung bei Frühgeborenen und Kleinkindern |
US7958887B2 (en) | 2006-03-10 | 2011-06-14 | Aradigm Corporation | Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations |
DE102006012174A1 (de) | 2006-03-16 | 2007-09-20 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapiegerätekompressor |
EP2012750B1 (en) | 2006-04-06 | 2018-02-21 | Insmed Incorporated | Methods for coacervation induced liposomal encapsulation and formulations thereof |
DE102006017002B3 (de) | 2006-04-11 | 2007-01-11 | Pari GmbH Spezialisten für effektive Inhalation | Inhalationstherapievorrichtung mit mehrfachen Düsen |
USD583928S1 (en) | 2006-04-27 | 2008-12-30 | Pari Pharama Gmbh | Nebulizer |
US20080131497A1 (en) | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8071127B2 (en) | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US8119156B2 (en) | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
US20080108104A1 (en) * | 2006-11-02 | 2008-05-08 | Colorado State University Research Foundation | Identification of bacterial species and subspecies using lipids |
EP1927373B1 (en) | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
EP2491932A3 (en) * | 2007-02-09 | 2012-12-12 | United Therapeutics Corporation | Use of biomarkers for monitoring the course of treatment of a pulmonary disease upon treatment with treprostinil |
DE502007002037D1 (de) | 2007-04-11 | 2009-12-31 | Pari Gmbh | Aerosoltherapievorrichtung |
WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
WO2008137917A1 (en) | 2007-05-07 | 2008-11-13 | Transave, Inc. | Method of treating bacterial infections with antibacterial formulations |
US9333214B2 (en) * | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
UA27298U (en) | 2007-06-13 | 2007-10-25 | Method for preventing pleural empyema after pneumonectomy | |
UA27804U (en) | 2007-07-26 | 2007-11-12 | Method for preventing respiratory complications after surgery in lungs and pleura | |
EP2030644A1 (en) | 2007-08-31 | 2009-03-04 | PARI Pharma GmbH | Aerosols for sinunasal drug delivery |
NZ562236A (en) * | 2007-10-05 | 2010-04-30 | Univ Otago | Detection of volatile compounds as markers for Mycobacteria tuberculosis |
CN101917972A (zh) | 2007-10-23 | 2010-12-15 | 特兰萨夫公司 | 脂质体万古霉素制剂 |
KR101303180B1 (ko) | 2007-11-09 | 2013-09-09 | 삼성전자주식회사 | 수직채널 트랜지스터를 구비한 반도체 메모리 소자 및 그제조 방법 |
DE102007056462B4 (de) | 2007-11-23 | 2011-10-27 | Pari Pharma Gmbh | Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen |
ES2884673T3 (es) | 2008-04-08 | 2021-12-10 | Melinta Therapeutics Inc | Oritavancina para inhibir y tratar biopelículas |
DE102008022987A1 (de) | 2008-05-09 | 2009-11-12 | Pari Pharma Gmbh | Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler |
AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
CA2754677A1 (en) | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
EP2248517B1 (en) | 2009-05-08 | 2014-03-26 | PARI Pharma GmbH | Concentrated mast cell stabilizing pharmaceutical formulations |
DE102009026636B4 (de) | 2009-06-02 | 2011-04-14 | Pari Pharma Gmbh | Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers |
HUE032278T2 (en) | 2009-07-17 | 2017-09-28 | Nektar Therapeutics | Compositions and procedures for driving sealed atomizers |
AU2010273955B2 (en) | 2009-07-17 | 2015-08-06 | Nektar Therapeutics | Negatively biased sealed nebulizers systems and methods |
WO2011010260A1 (en) | 2009-07-22 | 2011-01-27 | Koninklijke Philips Electronics N.V. | Thermal flow sensor integrated circuit with low response time and high sensitivity |
WO2011038901A1 (en) | 2009-09-29 | 2011-04-07 | Activaero Gmbh | Improved method for treatment of patients with cystic fibrosis |
WO2011049960A2 (en) | 2009-10-21 | 2011-04-28 | Otonomy, Inc. | Compositions and methods for the treatment of sinonasal disorders |
US8536220B2 (en) | 2010-01-26 | 2013-09-17 | Murray Fulgham | Supplement composition and method of use |
WO2011108955A1 (en) | 2010-03-03 | 2011-09-09 | Universidade De Coimbra | Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s) |
US9168225B2 (en) | 2010-04-23 | 2015-10-27 | The Board Of Trustees Of The University Of Illinois | Nano-hybrid delivery system for sequential utilization of passive and active targeting |
CA3102008A1 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
CN106074461A (zh) | 2010-07-12 | 2016-11-09 | 赛利亚医药公司 | 通过氨基糖苷气雾给药治疗肺部感染 |
AU2010359346B2 (en) | 2010-08-20 | 2015-01-29 | Dr. Reddy's Laboratories Sa | Phospholipid depot |
WO2012047674A2 (en) * | 2010-09-27 | 2012-04-12 | Microdose Therapeutx, Inc. | Methods and compositions for disease treatment using inhalation |
ES2899621T3 (es) | 2010-09-29 | 2022-03-14 | Pulmatrix Operating Co Inc | Polvos secos catiónicos que comprenden sal de magnesio |
EP2457609A1 (en) | 2010-11-24 | 2012-05-30 | PARI Pharma GmbH | Aerosol generator |
AU2012212269B2 (en) | 2011-01-31 | 2016-05-19 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
CA2836643C (en) | 2011-05-19 | 2017-11-14 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
WO2012168181A1 (en) | 2011-06-08 | 2012-12-13 | Pari Pharma Gmbh | Aerosol generator |
PL3597644T3 (pl) | 2011-10-18 | 2022-01-17 | Dicerna Pharmaceuticals, Inc. | Aminowe lipidy kationowe i ich zastosowania |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
CA2857604A1 (en) | 2011-12-22 | 2013-06-27 | Nuvo Research Gmbh | Liposomal chlorite or chlorate compositions |
US20130280174A1 (en) | 2012-04-20 | 2013-10-24 | The Gillette Company | Personal care composition comprising metathesized unsaturated polyol esters |
US9925295B2 (en) | 2012-05-09 | 2018-03-27 | Amedica Corporation | Ceramic and/or glass materials and related methods |
KR102277921B1 (ko) * | 2012-05-21 | 2021-07-14 | 인스메드 인코포레이티드 | 폐 감염을 치료하기 위한 시스템 |
US9314532B2 (en) * | 2012-08-10 | 2016-04-19 | University Of North Texas Health Science Center | Drug delivery vehicle |
US20150246137A1 (en) | 2012-09-27 | 2015-09-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
CA2891487A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
US20160193148A1 (en) | 2013-08-01 | 2016-07-07 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
US9198359B2 (en) | 2013-09-20 | 2015-12-01 | Deere & Company | Frame for a reciprocating sieve |
US9987227B2 (en) | 2013-10-22 | 2018-06-05 | Aradigm Corporation | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile |
CA2943049A1 (en) | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
US20160120806A1 (en) | 2014-04-08 | 2016-05-05 | Aradigm Corporation | Nanocrystals formed in a microenvironment |
US9968555B2 (en) | 2014-04-08 | 2018-05-15 | Aradigm Corporation | Liposomal formulations that form drug nanocrystals after freeze-thaw |
PL3142643T3 (pl) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Sposoby leczenia zakażeń płuc prątkami niegruźliczymi |
KR102079585B1 (ko) | 2014-08-29 | 2020-02-21 | 이엠디 밀리포어 코포레이션 | 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템 |
EP3271057B1 (en) | 2015-03-19 | 2019-09-04 | The University of Connecticut | Systems and methods for continuous manufacturing of liposomal drug formulations |
CA2989884A1 (en) | 2015-07-09 | 2017-01-12 | Insmed Incorporated | Compositions and methods for treating lung diseases and lung injury |
WO2017087876A1 (en) | 2015-11-18 | 2017-05-26 | Insmed Incorporated | Compositions and methods for treating bacterial infections |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
CN112584821A (zh) | 2018-05-02 | 2021-03-30 | 英斯梅德股份有限公司 | 脂质体药物配制品的制造方法 |
-
2015
- 2015-05-15 PL PL15791964T patent/PL3142643T3/pl unknown
- 2015-05-15 US US15/311,488 patent/US10238675B2/en active Active
- 2015-05-15 EP EP20182665.8A patent/EP3766501B1/en active Active
- 2015-05-15 LT LTEP18203799.4T patent/LT3466432T/lt unknown
- 2015-05-15 KR KR1020167035068A patent/KR102447412B1/ko active IP Right Grant
- 2015-05-15 ES ES15791964T patent/ES2755941T3/es active Active
- 2015-05-15 WO PCT/US2015/031079 patent/WO2015175939A1/en active Application Filing
- 2015-05-15 NZ NZ726256A patent/NZ726256A/en unknown
- 2015-05-15 PL PL18203799T patent/PL3466432T3/pl unknown
- 2015-05-15 BR BR112016026699-4A patent/BR112016026699B1/pt not_active IP Right Cessation
- 2015-05-15 PT PT157919648T patent/PT3142643T/pt unknown
- 2015-05-15 DK DK15791964.8T patent/DK3142643T3/da active
- 2015-05-15 KR KR1020227032656A patent/KR102489036B1/ko active IP Right Grant
- 2015-05-15 SI SI201530934T patent/SI3142643T1/sl unknown
- 2015-05-15 CA CA2949078A patent/CA2949078C/en active Active
- 2015-05-15 MX MX2016014921A patent/MX2016014921A/es active IP Right Grant
- 2015-05-15 ES ES18203799T patent/ES2820226T3/es active Active
- 2015-05-15 EP EP18203799.4A patent/EP3466432B1/en active Active
- 2015-05-15 ES ES20182665T patent/ES2926985T3/es active Active
- 2015-05-15 RS RS20201143A patent/RS60827B1/sr unknown
- 2015-05-15 EP EP22182229.9A patent/EP4122470B1/en active Active
- 2015-05-15 DK DK18203799.4T patent/DK3466432T3/da active
- 2015-05-15 KR KR1020237001082A patent/KR102657132B1/ko active IP Right Grant
- 2015-05-15 LT LT15791964T patent/LT3142643T/lt unknown
- 2015-05-15 US US14/713,926 patent/US9895385B2/en active Active
- 2015-05-15 MX MX2020010726A patent/MX2020010726A/es unknown
- 2015-05-15 JP JP2017512871A patent/JP6646653B2/ja active Active
- 2015-05-15 PT PT182037994T patent/PT3466432T/pt unknown
- 2015-05-15 KR KR1020247003025A patent/KR20240018675A/ko not_active Application Discontinuation
- 2015-05-15 EP EP15791964.8A patent/EP3142643B1/en active Active
- 2015-05-15 AU AU2015258947A patent/AU2015258947B2/en active Active
- 2015-05-15 SI SI201531365T patent/SI3466432T1/sl unknown
- 2015-05-15 CN CN201580038417.XA patent/CN106535877A/zh active Pending
- 2015-05-15 HU HUE18203799A patent/HUE051440T2/hu unknown
- 2015-05-15 ME MEP-2019-271A patent/ME03536B/me unknown
-
2018
- 2018-01-09 US US15/866,143 patent/US20180185401A1/en not_active Abandoned
- 2018-06-13 US US16/007,075 patent/US10251900B2/en active Active
-
2019
- 2019-01-17 US US16/250,476 patent/US10398719B2/en active Active
- 2019-01-31 US US16/263,648 patent/US10751355B2/en active Active
- 2019-07-18 US US16/515,303 patent/US10588918B2/en active Active
- 2019-10-03 HR HRP20191805TT patent/HRP20191805T1/hr unknown
- 2019-10-04 CY CY20191101044T patent/CY1122129T1/el unknown
-
2020
- 2020-01-10 JP JP2020002791A patent/JP6892529B2/ja active Active
- 2020-01-31 US US16/778,506 patent/US10828314B2/en active Active
- 2020-07-07 AU AU2020204530A patent/AU2020204530B2/en active Active
- 2020-07-15 US US16/930,134 patent/US11446318B2/en active Active
- 2020-09-24 US US17/031,744 patent/US11395830B2/en active Active
- 2020-10-06 CY CY20201100936T patent/CY1123411T1/el unknown
-
2021
- 2021-05-27 JP JP2021089011A patent/JP7212717B2/ja active Active
-
2022
- 2022-06-21 US US17/845,688 patent/US20220395524A1/en active Pending
- 2022-08-08 US US17/883,491 patent/US20230330119A1/en active Pending
- 2022-10-07 US US17/962,115 patent/US20230037417A1/en active Pending
-
2023
- 2023-01-13 JP JP2023003885A patent/JP2023033417A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191805T1 (hr) | Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća | |
JP2017515913A5 (hr) | ||
JP2015513309A5 (hr) | ||
RU2019100425A (ru) | Новая доза и препаративная форма | |
HRP20201761T1 (hr) | Prilagođeni liposomi za tretman bakterijskih infekcija | |
JP2019500318A (ja) | 細菌感染症を治療するための組成物及び方法 | |
JP2015515992A5 (hr) | ||
JP2016501233A (ja) | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 | |
JP2013515022A (ja) | 相乗的抗ウイルス組成物及びその使用 | |
HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
BR112012004692B1 (pt) | Solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano | |
JP2016505050A5 (hr) | ||
JP2009534367A5 (hr) | ||
HRP20201515T1 (hr) | Postupci za liječenje plućnih ne-tuberkuloznih mikobakterijskih infekcija | |
Hayes et al. | Revisiting an old therapy for tuberculosis | |
JP2024511419A (ja) | 非結核性抗酸菌肺疾患を治療するための併用療法 | |
Vutikullird et al. | PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF FLUTICASONE PROPIONATE MULTIDOSE DRY POWDER INHALER AND FLUTICASONE DISKUS (R) ADMINISTERED IN HEALTHY SUBJECTS: AN OPEN-LABEL, RANDOMIZED, THREE-PERIOD CROSSOVER, SINGLE-DOSE STUDY. | |
JP2015512439A5 (hr) | ||
Tlatelpa Romero et al. | Effect Of Inhaled Surfactant And Phosphatidylethanolamine On Bleomycin-Induced Lung Fibrosis In Mice | |
Shirk et al. | Unlabeled uses of nebulized medications [corrected][published erratum appears in AM J HEALTH SYST PHARM AJHP 2006 Nov 1; 63 (21): 2044]. | |
JP2015500841A5 (hr) | ||
EA201892706A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
UA69564U (uk) | Композіція назальна у вигляді розчину для краплинного або аерозольного введення | |
RU2011106753A (ru) | Способы введения топических противогрибковых препаратов для лечения грибковых инфекций |